Ted Burns
Affiliations: | Neurology | University of Virginia, Charlottesville, VA |
Google:
"Ted Burns"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Hehir MK, Conaway M, St Sauveur AB, et al. (2023) Measuring treatment adverse event burden in myasthenia gravis: Single-center prospective evaluation utilizing the Adverse Event Unit (AEU). Muscle & Nerve |
| Hehir MK, Conaway M, Clark EM, et al. (2022) The Adverse Event Unit (AEU): A novel metric to measure the burden of treatment adverse events. Plos One. 17: e0262109 |
| Nowak RJ, Coffey CS, Goldstein JM, et al. (2021) Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study. Neurology |
| Barohn RJ, Gajewski B, Pasnoor M, et al. (2020) Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS): Bayesian Adaptive Comparative Effectiveness Randomized Trial. Jama Neurology |
| Machado P, Barohn R, McDermott M, et al. (2019) P.02Phase 2/3 study of Arimoclomol in sporadic inclusion body myositis: study design Neuromuscular Disorders. 29 |
| Clifford KM, Hobson-Webb LD, Benatar M, et al. (2018) Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis. Muscle & Nerve |
| Kolb N, Burns T. (2018) Clinical research in chemotherapy-induced peripheral neuropathy: How, what, and when. Neurology |
| Gwathmey KG, Sadjadi R, Horton WB, et al. (2018) Validation of a simple disease-specific, quality-of-life measure for diabetic polyneuropathy: CAPPRI. Neurology |
| Hehir MK, Hobson-Webb LD, Benatar M, et al. (2017) Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review. Neurology |
| Burns TM, Smith GA, Allen JA, et al. (2015) Editorial by concerned physicians: Unintended effect of the Orphan Drug Act on the potential cost of 3,4-diaminopyridine. Muscle & Nerve |